In patients with type 2 diabetes with NAFLD, the threshold for glucagon-like peptide-1 analogues such as Liraglutide and Semaglutide, which are associated with weight loss and NASH resolution, needs to be lower [41, 42]. This evidence concerns the gene GCG and type 2 diabetes mellitus.